Key facts
- This page summarizes Peter Rahmer's Form 4 filing for Relay Therapeutics, Inc. (RLAY).
- 4 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 30 Jan 2025, 21:16.
Peter Rahmer - 28 Jan 2025 Form 4 Insider Report for Relay Therapeutics, Inc. (RLAY)
- Reporting relationship
- Chief Corporate Development Officer
- Issuer ticker
- RLAY
- Reported as of
- 28 Jan 2025
- Net transaction value
- -$204,753
- SEC form
- 4
- Accepted by SEC
- 30 Jan 2025, 21:16:04 UTC
- Prior SEC filing
- 14 Jan 2025
- Next SEC filing
- 31 Mar 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Brian Adams, as Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Filing notes and source
Key filing fact
Peter Rahmer filed Form 4 for Relay Therapeutics, Inc. (RLAY) on 30 Jan 2025.
Change
- Previous filing in this sequence was filed on 14 Jan 2025.
- Current net transaction value: -$204,753.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
RLAY
transaction
Common Stock
Sale
- Transaction value
- $7,746
- Shares
- -1,673
- Change %
- -0.54%
- Price
- $4.63
- Shares after
- 307,081
- Date
- 28 Jan 2025
- Ownership
- Direct
- Footnotes
- F1, F2
RLAY
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +139,141
- Change %
- +45%
- Price
- $0.000000
- Shares after
- 446,222
- Date
- 28 Jan 2025
- Ownership
- Direct
- Footnotes
- F3, F4
RLAY
transaction
Common Stock
Sale
- Transaction value
- $120,762
- Shares
- -26,541
- Change %
- -5.9%
- Price
- $4.55
- Shares after
- 419,681
- Date
- 29 Jan 2025
- Ownership
- Direct
- Footnotes
- F5, F6
RLAY
transaction
Common Stock
Sale
- Transaction value
- $76,245
- Shares
- -17,250
- Change %
- -4.1%
- Price
- $4.42
- Shares after
- 402,431
- Date
- 30 Jan 2025
- Ownership
- Direct
- Footnotes
- F7, F8
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 8 footnotes
Footnote F1
Sale of shares to cover the reporting person's income tax withholding obligations upon the vesting of 5,505 shares of restricted stock units ("RSUs") on January 27, 2025. The reporting person had no discretion with respect to such sale, which was transacted in accordance with the Issuer's policies regarding the vesting of RSUs.
Footnote F2
Includes 284,033 shares underlying RSUs.
Footnote F3
Represents RSUs granted to the reporting person pursuant to the Issuer's 2020 Stock Option and Incentive Plan. Each RSU represents a contingent right to receive one share of the Issuer's common stock upon vesting.
Footnote F4
Includes 423,174 shares underlying RSUs.
Footnote F5
Sale of shares to cover the reporting person's income tax withholding obligations upon the vesting of 100,000 shares of RSUs on January 28, 2025. The reporting person had no discretion with respect to such sale, which was transacted in accordance with the Issuer's policies regarding the vesting of RSUs.
Footnote F6
Includes 323,174 shares underlying RSUs.
Footnote F7
Sale of shares to cover the reporting person's income tax withholding obligations upon the vesting of 69,570 shares of RSUs on January 29, 2025. The reporting person had no discretion with respect to such sale, which was transacted in accordance with the Issuer's policies regarding the vesting of RSUs.
Footnote F8
Includes 253,604 shares underlying RSUs.
SEC remarks
Chief Corporate Development Officer